GNLX

Over the past six months, Genelux Corp. (GNLX) stock declined by 39.18%, with a 52-week high of $8.54 and a low of $2.29. Key events included the publication of positive clinical data for Olvi-Vec in SCLC and ovarian cancer in September and June 2026, respectively. The company reported its second-quarter financial results in August 2026 and fourth-quarter and full-year 2025 results in March 2026, reiterating expectations for Phase 3 ovarian cancer trial data in the second half of 2026. In January 2026, Genelux raised $18.5 million in net proceeds from a stock offering. Analyst ratings saw a downgrade to 'sell' by Wall Street Zen in April 2026, followed by an upgrade back to 'hold' in March 2026, and Benchmark cut its price target while maintaining a 'speculative buy' rating.